DataMeds AI To Collaborate With REBOOT Health AI To Integrate Its GLP Management Platform Into Its Health Lives Here Mobile App Under License Agreement

DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has entered into an exclusive license, revenue sharing and marketing agreement with REBOOT Health AI, Inc. ("REBOOT") for Direct-to-Consumer (DTC) rights in the United States to REBOOT's proprietary care management platform. The Companies will work together to tailor the platform for use in the Health Lives Here mobile application for patients taking GLP-1 receptor agonist medications (the "GLP Management Platform") leveraging the patents and patent applications (the "IP") under the license. REBOOT is an operating subsidiary of Data Health Partners, Inc.

Under the terms of the agreement, DataMEDS agreed to work with REBOOT to integrate the GLP Management Platform into its recently launched Health Lives Here mobile application and share revenue generated from subscriptions related to the use of the GLP Management Platform. The Company believes that this license provides it with the unique opportunity to integrate REBOOT's data-driven, evidence-based outcome optimization technology with DataMEDS' mobile application, offering a holistic approach to GLP-1 management. DataMEDS plans to work with REBOOT to develop and integrate the REBOOT technology into its GLP Management Platform, conduct pilot programs, and launch commercially.